RecruitingPHASE2, PHASE3NCT05401071

Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

Studying Tuberculosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Huashan Hospital
Principal Investigator: Wenhong Zhang, PhD.
Huashan Hospital of Fudan University，Shanghai，China
Intervention: Short Regimen with Rifapentine 10mg/kg(other)
Enrollment: 2442 target
Eligibility: 18-60 years · All sexes
Timeline: 2023 – 2027

Study locations (6)

Guiyang Public Health Clinical Center, Guiyang, Guizhou, China
People's Hospital of Qiandongnan, Kaili, Guizhou, China
The Third People's Hospital of Liupanshui, Liupanshui, Guizhou, China
Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
Department of Infectious Disease, Huashan Hospital, Shanghai, Shanghai Municipality, China
People's Hospital of Zhuji, Zhejiang Province, Zhuji, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05401071 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis →

← Back to all trials